Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120222 · ClinicalTrials.gov registry record · Phase 1
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
A Phase 1 study, sponsored by Kari Kendra.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02120222: Completed Phase 1 study, sponsored by Kari Kendra.
NCT02120222 is a Phase 1 study that has completed, run by Kari Kendra. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02120222, a Phase 1 study, has completed, sponsored by Kari Kendra.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.
Primary Outcome
Types of toxicities, incidences and severity will be summarized by descriptive statistics such as frequencies/proportions.
Interventions
- OTHER Correlative studies
- DRUG selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-08-22 |
| Est. Completion | 2018-04-08 |
| Phase | Phase 1 |
What the finished NCT02120222 record still lists
NCT02120222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Correlative studies is the first listed.
NCT02120222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02120222 about?
NCT02120222 is a clinical study titled "Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery". This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.
What is the current status of trial NCT02120222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-08-22. Estimated completion is 2018-04-08.
What interventions are being tested in trial NCT02120222?
The interventions under investigation include: Correlative studies (OTHER), selinexor (DRUG).
Who is sponsoring clinical trial NCT02120222?
This trial is sponsored by Kari Kendra, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02120222's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI